Technological watch

ABT plant ups production capacity biobased ECH to 120 kT/pa - Bio-based News -

The company is expanding its production of bio-based epichlorohydrin (ECH) to 120 kT/pa – an increase of 20,000 metric tons per year. Permission for this increase was granted by the Industrial Estate Authority of Thailand.

The capacity increase at ABT’s plant was made possible thanks to improvements in process efficiency and process optimizations in production. Less waste is also being produced at the plant due to optimized recycling technology.

A wholly-owned subsidiary of the Vinythai public company, ABT has produced its bio-based ECH since 2012 using a patented technology, based on natural and renewable glycerine instead of propylene, a fossil fuel derivative.

Managing director at ABT, Masaki Takahashi, expressed his thanks to the Industrial Estate Authority of Thailand for granting permission for this capacity increase at our plant.
“We provide the most sustainable ECH on the market and demand for it continues to grow. We are glad that we can continue to serve downstream users around the globe who are committed to sustainability.”

ABT produces a bio-based epichlorohydrin (ECH) using an innovative and patented technology. Its bio-based ECH is based on natural, renewable glycerine and it is the most sustainable ECH on the market. ABT has operated its world-class manufacturing unit in Map Ta Phut since February 2012. Certified by the Roundtable on Sustainable Biomaterials (RSB) since 2015, ABT is wholly-owned by Vinythai Public Company Limited and both companies strongly adhere to sustainability and social responsibility commitments. ABT and Vinythai received a Green Industry Award Level 4 (Green Culture) from the Thailand Department of Industrial Works for their commitment to environmental care.

Source: bioplastics MAGAZINE, press release, 2020-03-02.

Publication date: 17/03/2020

Bio-based News


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 870292.